血液透析联合血液灌注治疗尿毒症临床分析

Clinical analysis of treatment of uremia with hemodialysis combined blood perfusion

目的:探讨血液透析(HD)联合血液灌注(HP)治疗尿毒症患者的临床疗效。方法:维持性透析患者30例,15例采用血液透析(HD)联合血液灌注(HP)治疗,为联合组。15例只采用血液透析治疗,为对照组。对两组治疗后的血清肌酐(SCr)、β2微球蛋白(β2-MG)、甲状旁腺激素(PTH)、尿素氮(BUN)含量及症状缓解情况进行比较。结果:联合组治疗前后SCr、β2-MG、PTH、BUN都显著降低,差异具有统计学意义(P<0.05),且症状缓解较好。对照组改善不明显。结论:血液透析联合血液灌注对尿毒症的治疗比较有优势。

Objective：To explore the clinical effect of treatment of uremic patients with hemodialysis （HD） joint hemoperfusion（HP）. Methods：30 cases of chronic hemodialysis patients, 15 cases were treated with hemodialysis （HD） joint hemoperfusion （HP） treatment, the combination group. 15 cases of hemodialysis therapy using only for the control group. The two groups after treatment serum creatinine （SCr）, β2 microglobulin （β2-MG）, parathyroid hormone （PTH）, urea nitrogen （BUN） levels and the symptom relief were compared. Results： SCr, β2-MG, PTH, BUN were significantly lower in the combination group before and after treatment, the difference was significant （P〈0.05）, and the symptoms relieved better. The control group had no obvious improvement. Conclusion：Hemodialysis joint hemoperfusion treatment of uremia is more advantage.